IMPACT BIOMEDICAL INC
For the period ended Dec 31, 2023. Filed Feb 20, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 20, 2024
IBO$4.62+6.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Impact BioMedical, Inc. and Subsidiaries
| 2023 | 2022 | |
|---|---|---|
| Cash flows from operating activities: | ||
| Net loss | $(4,407,000) | $(7,255,000) |
| Adjustments to reconcile net loss to net cash used by operating activities: | ||
| Depreciation and amortization | 1,120,000 | 1,113,000 |
| Deferred tax benefit | - | (621,000) |
| Impairment of other investments | - | 4,100,000 |
| Decrease (increase) in assets: | ||
| Other receivables | (128,000) | - |
| Prepaid expenses and other current assets | 104,000 | (60,000) |
| Increase (decrease) in liabilities: | ||
| Accounts payable | 293,000 | 424,000 |
| Accrued expenses | 167,000 | 57,000 |
| Net cash used by operating activities | (2,851,000) | (2,242,000) |
| Cash flows from investing activities: | ||
| Purchase of property, plant and equipment | (18,000) | (276,000) |
| Purchase of investment | - | (65,000) |
| Note receivable investment, net | 3,000 | (8,000) |
| Net cash used by investing activities | (15,000) | (349,000) |
| Cash flows from financing activities: | ||
| Borrowings from note payable, related party | 2,865,000 | 2,547,000 |
| Net cash provided by financing activities | 2,865,000 | 2,547,000 |
| Net decrease in cash | (1,000) | (44,000) |
| Cash and cash equivalents at beginning of year | 2,000 | 46,000 |
| Cash and cash equivalents at end of year | $1,000 | $2,000 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.